Azirkitug Biosimilar Monoclonal Antibody (CCR8) for Research

Cat No.: GMP-Bios-INN-1092

Anti-CCR8/CKR-L1/CDw198 therapeutic antibody (Pre-made Azirkitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Azirkitug (development code ABBV-514) is a humanized monoclonal antibody targeting CCR8. It is developed by AbbVie for solid tumors. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1092-1mg 1mg 3090
GMP-Bios-INN-1092-10mg 10mg
GMP-Bios-INN-1092-100mg 100mg
GMP-Bios-INN-1092-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Azirkitug biosimilar, Whole mAb, Anti-CCR8/CKR-L1/CDw198 Antibody: Anti-CCR8/CDw198/C-C chemokine receptor type 8/C-C CKR-8 therapeutic antibody
INN Name Azirkitug
Target CCR8/CKR-L1/CDw198
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-I
Est. Status Discontinued
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies AbbVie
Conditions Approved na
Conditions Active na
Conditions Discontinued Non-small cell lung cancer;Squamous cell cancer
Production na
Development Tech TBC